Brokerages Anticipate Baxter International Inc (BAX) Will Announce Quarterly Sales of $2.62 Billion

Equities analysts predict that Baxter International Inc (NYSE:BAX) will post sales of $2.62 billion for the current quarter, according to Zacks. Six analysts have made estimates for Baxter International’s earnings. The lowest sales estimate is $2.61 billion and the highest is $2.67 billion. Baxter International reported sales of $2.48 billion in the same quarter last year, which indicates a positive year over year growth rate of 5.6%. The company is scheduled to announce its next quarterly earnings report on Wednesday, April 25th.

On average, analysts expect that Baxter International will report full year sales of $2.62 billion for the current year, with estimates ranging from $11.21 billion to $11.40 billion. For the next financial year, analysts forecast that the business will post sales of $11.72 billion per share, with estimates ranging from $11.39 billion to $11.91 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Baxter International.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.77 billion. Baxter International had a return on equity of 15.12% and a net margin of 6.79%. Baxter International’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business posted $0.57 earnings per share.

A number of analysts have issued reports on the company. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price target for the company in a report on Tuesday, October 24th. Raymond James Financial raised Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price target for the company in a report on Wednesday, January 3rd. Royal Bank of Canada reaffirmed a “hold” rating and set a $66.00 price target on shares of Baxter International in a report on Wednesday, November 22nd. JPMorgan Chase & Co. raised Baxter International from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Finally, Bank of America reaffirmed a “hold” rating on shares of Baxter International in a report on Wednesday, November 22nd. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Baxter International presently has a consensus rating of “Buy” and a consensus price target of $70.36.

In other news, SVP Jeanne K. Mason sold 33,350 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the sale, the senior vice president now directly owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the company. Colony Group LLC purchased a new stake in shares of Baxter International in the 3rd quarter valued at about $6,966,000. Toronto Dominion Bank lifted its holdings in shares of Baxter International by 8.6% in the 3rd quarter. Toronto Dominion Bank now owns 212,015 shares of the medical instruments supplier’s stock valued at $13,304,000 after purchasing an additional 16,835 shares during the last quarter. Johnson Financial Group Inc. lifted its holdings in shares of Baxter International by 15.5% in the 3rd quarter. Johnson Financial Group Inc. now owns 21,038 shares of the medical instruments supplier’s stock valued at $1,320,000 after purchasing an additional 2,825 shares during the last quarter. Sawyer & Company Inc purchased a new stake in shares of Baxter International in the 4th quarter valued at about $327,000. Finally, Canada Pension Plan Investment Board lifted its holdings in shares of Baxter International by 35.8% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock valued at $88,669,000 after purchasing an additional 372,500 shares during the last quarter. 83.54% of the stock is owned by institutional investors and hedge funds.

Baxter International (BAX) opened at $64.31 on Monday. The stock has a market capitalization of $35,040.00, a price-to-earnings ratio of 49.47, a P/E/G ratio of 1.82 and a beta of 0.78. Baxter International has a fifty-two week low of $48.58 and a fifty-two week high of $72.58. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/brokerages-anticipate-baxter-international-inc-bax-will-announce-quarterly-sales-of-2-62-billion.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Get a free copy of the Zacks research report on Baxter International (BAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply